Tien Liang Biotech Co., Ltd.

As of June 30, 2026, Tien Liang Biotech Co., Ltd. carries a market capitalization of 3.13B, placing it among publicly traded companies globally. Its enterprise value stands at 3.53B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Tien Liang Biotech Co., Ltd. has 45.76M shares outstanding.

As of June 30, 2026, Tien Liang Biotech Co., Ltd. trades at a trailing price-to-earnings ratio of 45.19. The price-to-sales ratio is 4.80, and the price-to-book ratio stands at 6.02.

As of June 30, 2026, Tien Liang Biotech Co., Ltd. trades at an EV/EBITDA multiple of 210.19 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 5.42 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 623.26 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Tien Liang Biotech Co., Ltd. trades at an EV/FCF ratio of 116.41, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 3.53B versus a market cap of 3.13B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Tien Liang Biotech Co., Ltd. maintains a current ratio of 0.45, meaning it holds 0.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 115.31, indicating elevated leverage, while an interest coverage ratio of 1.30 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Tien Liang Biotech Co., Ltd. posted a return on equity (ROE) of 14.25, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 0.54 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 6.06, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 7.82, useful for judging operating efficiency across full business cycles. The company generates approximately 8.24M in revenue per employee across its workforce of 79.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.53 indicates how many times Tien Liang Biotech Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Tien Liang Biotech Co., Ltd. recorded 189,000.00 in income tax expense. That works out to an effective tax rate of 0.27, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 69.28M, leaving 69.09M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Tien Liang Biotech Co., Ltd.'s stock has gained approximately 13.28% over the past 52 weeks. The 50-day moving average sits at 61.72, while the 200-day moving average is 52.61.

Over the twelve months ended June 30, 2026, Tien Liang Biotech Co., Ltd. generated 650.87M in revenue and converted that into 69.09M in net income, yielding earnings per share of 1.51. EBITDA reached 16.78M, while operating income came in at 5.66M.

As of June 30, 2026, Tien Liang Biotech Co., Ltd. holds 197.11M in cash and equivalents against 598.75M in total debt, resulting in a net debt position of 431.65M. Total book value stands at 519.25M, with working capital of -388.17M providing operational flexibility.

Tien Liang Biotech Co., Ltd. produced 47.11M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -29.73M in capital expenditures, free cash flow totaled 17.38M - equivalent to 0.38 per share.

Over the twelve months ended June 30, 2026, Tien Liang Biotech Co., Ltd. posted a gross margin of 58.29, reflecting its pricing power and cost economics. The operating margin of 0.87 and net profit margin of 10.62 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 0.56, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -1.92, meaning Tien Liang Biotech Co., Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Tien Liang Biotech Co., Ltd.'s most recent stock split took place on September 24, 2008 with a 25:26 split ratio.

As of June 30, 2026, Tien Liang Biotech Co., Ltd. has an Altman Z-Score of 2.89, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.